Published in Am J Gastroenterol on September 20, 2011
The Cirrhosis Outpatient Optimization, Readmission & Safety Study (Vivify) | NCT02457988
Decreasing mortality among patients hospitalized with cirrhosis in the United States from 2002 through 2010. Gastroenterology (2015) 1.69
A Quality Improvement Initiative Reduces 30-Day Rate of Readmission for Patients With Cirrhosis. Clin Gastroenterol Hepatol (2015) 1.52
An Automated Telephone Monitoring System to Identify Patients with Cirrhosis at Risk of Re-hospitalization. Dig Dis Sci (2015) 1.43
Multidisciplinary management of patients with cirrhosis: a need for care coordination. Clin Gastroenterol Hepatol (2012) 1.02
An automated model using electronic medical record data identifies patients with cirrhosis at high risk for readmission. Clin Gastroenterol Hepatol (2013) 1.02
Risk factors for frequent readmissions and barriers to transplantation in patients with cirrhosis. PLoS One (2013) 0.98
Utility of models to predict 28-day or 30-day unplanned hospital readmissions: an updated systematic review. BMJ Open (2016) 0.91
Frailty as Tested by Gait Speed is an Independent Risk Factor for Cirrhosis Complications that Require Hospitalization. Am J Gastroenterol (2016) 0.85
Management of hepatic encephalopathy in the hospital. Mayo Clin Proc (2014) 0.85
Advanced disease, diuretic use, and marital status predict hospital admissions in an ambulatory cirrhosis cohort. Dig Dis Sci (2013) 0.83
A Rapid Bedside Screen to Predict Unplanned Hospitalization and Death in Outpatients With Cirrhosis: A Prospective Evaluation of the Clinical Frailty Scale. Am J Gastroenterol (2016) 0.83
The end-organ impairment in liver cirrhosis: appointments for critical care. Crit Care Res Pract (2012) 0.82
The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. Hepatology (2016) 0.82
Healthcare utilization in chronic liver disease: the importance of pain and prescription opioid use. Liver Int (2013) 0.81
Variation among United States hospitals in inpatient mortality for cirrhosis. Clin Gastroenterol Hepatol (2014) 0.80
Gut Microbiota Alterations can predict Hospitalizations in Cirrhosis Independent of Diabetes Mellitus. Sci Rep (2015) 0.80
Isoprene in the Exhaled Breath is a Novel Biomarker for Advanced Fibrosis in Patients with Chronic Liver Disease: A Pilot Study. Clin Transl Gastroenterol (2015) 0.79
Identifying cirrhosis patients for intensive disease management. Dig Dis Sci (2013) 0.79
Identifying patients with advanced chronic conditions for a progressive palliative care approach: a cross-sectional study of prognostic indicators related to end-of-life trajectories. BMJ Open (2016) 0.79
Evaluation of the impact of rehospitalization in the management of hepatic encephalopathy. Int J Gen Med (2015) 0.78
Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs. Hepat Med (2015) 0.78
Decompensated cirrhosis-related admissions in a large urban hospital in Uganda: prevalence, clinical and laboratory features and implications for planning patient management. Afr Health Sci (2013) 0.76
Increased EMR2 expression on neutrophils correlates with disease severity and predicts overall mortality in cirrhotic patients. Sci Rep (2016) 0.76
A care coordination program to optimize management of cirrhosis: real-life applicability and feasibility in the context of the Canadian health care system. Can J Gastroenterol Hepatol (2014) 0.75
Evaluation and Management of Hepatic Encephalopathy: Current Status and Future Directions. Gut Liver (2016) 0.75
Use of Palliative Care Consultation for Patients with End-Stage Liver Disease: Survey of Liver Transplant Service Providers. J Palliat Med (2016) 0.75
Impact of physician specialty on quality care for patients hospitalized with decompensated cirrhosis. PLoS One (2015) 0.75
Changes in Hospital Admissions and Mortality for Complications of Cirrhosis: Implications for Clinicians and Health Systems. Gut Liver (2016) 0.75
High Rate of Hospital Admissions Among Patients with Cirrhosis Seeking Care in US Emergency Departments. Dig Dis Sci (2015) 0.75
Quality of Care in the Cirrhotic Patient. Clin Transl Gastroenterol (2016) 0.75
Hospital Readmissions in Decompensated Cirrhosis. Am J Gastroenterol (2015) 0.75
Outcomes associated with a mandatory gastroenterology consultation to improve the quality of care of patients hospitalized with decompensated cirrhosis. J Hosp Med (2014) 0.75
Current state of knowledge of hepatic encephalopathy (part III): non-absorbable disaccharides. Metab Brain Dis (2016) 0.75
Prevalence of medication discrepancies in patients with cirrhosis: a pilot study. BMC Gastroenterol (2016) 0.75
Predictors of Early Readmission in Patients With Cirrhosis After the Resolution of Bacterial Infections. Am J Gastroenterol (2017) 0.75
Trends in 30-Day and 1-Year Mortality Among Patients Hospitalized With Cirrhosis From 2004 to 2013. Am J Gastroenterol (2017) 0.75
Symptom Domain Groups of the Patient-Reported Outcomes Measurement Information System Tools Independently Predict Hospitalizations and Re-hospitalizations in Cirrhosis. Dig Dis Sci (2017) 0.75
Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic Options. J Clin Transl Hepatol (2017) 0.75
Ascites, refractory ascites and hyponatremia in cirrhosis. Gastroenterol Rep (Oxf) (2017) 0.75
A New Look at Precipitants of Overt Hepatic Encephalopathy in Cirrhosis. Dig Dis Sci (2017) 0.75
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol (1992) 60.45
Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med (2009) 35.68
A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med (1995) 10.32
Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. JAMA (2004) 7.43
Posthospital care transitions: patterns, complications, and risk identification. Health Serv Res (2004) 4.55
Burden of liver disease in the United States: summary of a workshop. Hepatology (2002) 4.00
Use of structured letters to improve communication between hospital doctors and general practitioners. BMJ (1993) 2.10
Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clin Gastroenterol Hepatol (2010) 1.48
Chronic disease management for patients with cirrhosis. Gastroenterology (2010) 1.47
The effects of donor and recipient practices on transplant center finances. Am J Transplant (2008) 1.44
Nationwide increase in hospitalizations and hepatitis C among inpatients with cirrhosis and sequelae of portal hypertension. Clin Gastroenterol Hepatol (2007) 1.25
Prophylaxis with beta blockers as a performance measure of quality health care in cirrhosis. Gastroenterology (2006) 1.00
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med (2006) 7.35
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med (2006) 5.65
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology (2005) 3.95
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol (2013) 3.41
Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol (2005) 3.18
NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology (2002) 2.96
GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol (2005) 2.70
Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev (2012) 2.57
Outcomes of living donor liver transplantation for acute liver failure: the adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2008) 2.30
Hepatitis B therapy. Nat Rev Gastroenterol Hepatol (2011) 2.23
Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology (2007) 2.11
Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology (2003) 2.05
CD73 (ecto-5'-nucleotidase) hepatocyte levels differ across mouse strains and contribute to mallory-denk body formation. Hepatology (2013) 2.04
One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol (2005) 2.04
Modified Charlson comorbidity index for predicting survival after liver transplantation. Liver Transpl (2007) 1.96
Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology (2015) 1.87
Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology (2009) 1.80
Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl (2005) 1.76
Energy determinants GAPDH and NDPK act as genetic modifiers for hepatocyte inclusion formation. J Cell Biol (2011) 1.72
Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark (2007) 1.65
Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl (2007) 1.61
Characterization of the multiple conformational States of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker. J Virol (2006) 1.58
Renal outcomes after liver transplantation in the model for end-stage liver disease era. Liver Transpl (2009) 1.49
Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl (2005) 1.47
Liver transplantation outcomes among Caucasians, Asian Americans, and African Americans with hepatitis B. Liver Transpl (2009) 1.46
Patient involvement in healthcare is associated with higher rates of surveillance for hepatocellular carcinoma. J Clin Gastroenterol (2011) 1.46
Burden of cirrhosis on older Americans and their families: analysis of the health and retirement study. Hepatology (2012) 1.44
Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma. Am J Gastroenterol (2013) 1.39
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology (2011) 1.33
An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. Liver Transpl (2009) 1.31
Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance. J Hepatol (2008) 1.25
A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology (2013) 1.21
Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol (2011) 1.20
SRM targeted proteomics in search for biomarkers of HCV-induced progression of fibrosis to cirrhosis in HALT-C patients. Proteomics (2012) 1.11
Patient decision making about organ quality in liver transplantation. Liver Transpl (2011) 1.04
An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS One (2011) 1.04
Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology (2009) 1.03
Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial. J Hepatol (2005) 0.98
Does antiviral therapy prevent hepatocellular carcinoma? Antivir Ther (2011) 0.92
Impaired virion secretion by hepatitis B virus immune escape mutants and its rescue by wild-type envelope proteins or a second-site mutation. J Virol (2012) 0.90
Mallory-Denk bodies are associated with outcomes and histologic features in patients with chronic hepatitis C. Clin Gastroenterol Hepatol (2011) 0.90
Hepatitis B screening and vaccination practices in asian american primary care. Gut Liver (2013) 0.89
Monitoring antiviral resistance in patients receiving nucleos(t)ide analog therapies for hepatitis B: which method should be used? J Hepatol (2008) 0.89
Clinical relevance of cognitive scores in hepatitis C patients with advanced fibrosis. J Clin Exp Neuropsychol (2006) 0.88
CDC and USPSTF 2012 recommendations for screening for hepatitis C virus infection: overview and take-home messages. Clin Gastroenterol Hepatol (2013) 0.88
Who decides? Living donor liver transplantation for advanced hepatocellular carcinoma. Transplantation (2006) 0.86
Hepatitis B prevalence among Asian Americans in Michigan: an assessment to guide future education and intervention strategies. J Community Health (2010) 0.83
Histologic outcomes in hepatitis C-infected patients with varying degrees of virologic response to interferon-based treatments. Hepatology (2010) 0.82
Impact of the hepatitis B virus genotype on pre- and post-liver transplantation outcomes. Liver Transpl (2008) 0.81
Interferon-free treatment regimens for hepatitis C: are we there yet? Gastroenterology (2011) 0.80
Predicting cirrhosis and clinical outcomes in patients with advanced chronic hepatitis C with a panel of genetic markers (CRS7). Pharmacogenet Genomics (2011) 0.80
New approaches to optimize treatment responses in chronic hepatitis B. Antivir Ther (2010) 0.80
YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C. Liver Int (2011) 0.79
A comparative study of patients' attitudes toward clinical research in the United States and urban and rural China. Clin Transl Sci (2015) 0.78
No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C. J Affect Disord (2011) 0.78
Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. Am J Gastroenterol (2012) 0.78
CDC and USPSTF 2012 recommendations for screening for hepatitis C virus infection: overview and take-home messages. Gastroenterology (2013) 0.77
Should antiviral treatment be extended to patients with chronic hepatitis B and mildly elevated alanine aminotransferase? Hepatology (2010) 0.75
What is the optimal regimen for preventing hepatitis B recurrence after liver transplantation? Nat Clin Pract Gastroenterol Hepatol (2008) 0.75
Reply to Giannini and Trevisani. Am J Gastroenterol (2013) 0.75
Should treatment of hepatitis B patients be based solely on liver fibrosis? Clin Gastroenterol Hepatol (2013) 0.75
Should liver biopsies be performed on all hepatitis B carriers? Gastroenterology (2008) 0.75
Do guidelines preclude hepatitis B patients from receiving treatment? Hepatology (2009) 0.75
Population-Based Analysis and Projections of Liver Supply Under Redistricting. Transplantation (2017) 0.75
Authorship: who should be included and how should it be determined? Gastroenterology (2011) 0.75
A comparative study of patients' knowledge about hepatitis C in the United States and in urban and rural China. Hepatol Int (2014) 0.75